title: Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
abstract: Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.
authors.affiliation: University of Alabama, Department of Obstetrics and Gynecology, Birmingham 35294.
authors.forename: M E
authors.initials: ME
authors.lastname: Potter
authors.forename: E E
authors.initials: EE
authors.lastname: Partridge
authors.forename: H M
authors.initials: HM
authors.lastname: Shingleton
authors.forename: S J
authors.initials: SJ
authors.lastname: Soong
authors.forename: R Y
authors.initials: RY
authors.lastname: Kim
authors.forename: K D
authors.initials: KD
authors.lastname: Hatch
authors.forename: J M
authors.initials: JM
authors.lastname: Austin
mesh_terms: D002857:Chromium / Q000008:administration & dosage* / Q000627:therapeutic use; D017608:Chromium Compounds; D005260:Female; D006801:Humans; D007322:Instillation, Drug; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D010529:Peritoneal Cavity; D010710:Phosphates / Q000008:administration & dosage* / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D002857:Chromium; C509369:chromic phosphate